Last reviewed · How we verify
SP, chloroquine, amodiaquine, primaquine, artesunate
SP, chloroquine, amodiaquine, primaquine, artesunate is a Antimalarial combination therapy Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 3 development for Malaria treatment and transmission reduction (phase 3 development).
This is a fixed-dose combination of antimalarial drugs that work through multiple mechanisms to kill malaria parasites and reduce transmission.
This is a fixed-dose combination of antimalarial drugs that work through multiple mechanisms to kill malaria parasites and reduce transmission. Used for Malaria treatment and transmission reduction (phase 3 development).
At a glance
| Generic name | SP, chloroquine, amodiaquine, primaquine, artesunate |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Antimalarial combination therapy |
| Target | Multiple: heme polymerase, mitochondrial electron transport, gametocyte development |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | Phase 3 |
Mechanism of action
The combination includes chloroquine and amodiaquine (quinoline antimalarials that inhibit heme polymerization in parasites), primaquine (an 8-aminoquinoline that targets hypnozoites and gametocytes), and artesunate (an artemisinin derivative that generates reactive oxygen species). Together, these agents target different parasite life stages and reduce both clinical malaria and transmission potential.
Approved indications
- Malaria treatment and transmission reduction (phase 3 development)
Common side effects
- Gastrointestinal disturbance (nausea, vomiting, diarrhea)
- Headache
- Hemolysis (primaquine-related, in G6PD deficiency)
- Pruritus
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SP, chloroquine, amodiaquine, primaquine, artesunate CI brief — competitive landscape report
- SP, chloroquine, amodiaquine, primaquine, artesunate updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI
Frequently asked questions about SP, chloroquine, amodiaquine, primaquine, artesunate
What is SP, chloroquine, amodiaquine, primaquine, artesunate?
How does SP, chloroquine, amodiaquine, primaquine, artesunate work?
What is SP, chloroquine, amodiaquine, primaquine, artesunate used for?
Who makes SP, chloroquine, amodiaquine, primaquine, artesunate?
What drug class is SP, chloroquine, amodiaquine, primaquine, artesunate in?
What development phase is SP, chloroquine, amodiaquine, primaquine, artesunate in?
What are the side effects of SP, chloroquine, amodiaquine, primaquine, artesunate?
What does SP, chloroquine, amodiaquine, primaquine, artesunate target?
Related
- Drug class: All Antimalarial combination therapy drugs
- Target: All drugs targeting Multiple: heme polymerase, mitochondrial electron transport, gametocyte development
- Manufacturer: London School of Hygiene and Tropical Medicine — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Parasitology
- Indication: Drugs for Malaria treatment and transmission reduction (phase 3 development)
- Compare: SP, chloroquine, amodiaquine, primaquine, artesunate vs similar drugs
- Pricing: SP, chloroquine, amodiaquine, primaquine, artesunate cost, discount & access